{"filing":{"accession_number":"0001104659-26-065908","cik":"0001650664","ticker":"EDIT","company_name":"Editas Medicine, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"tm2615565d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1650664/000110465926065908/tm2615565d1_8k.htm"},"events":[{"id":8947,"run_id":7853,"accession_number":"0001104659-26-065908","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Editas disclosed positive preclinical data for EDIT-401 demonstrating robust reductions in LDL-C, Lp(a), and ApoB in non-human primates, along with plans to initiate a first-in-human clinical trial in 2026 and FDA pre-IND feedback. This announcement represents material progress on a lead pipeline candidate for a gene-editing biotech company where clinical advancement is a key value driver.","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1404,"accession_number":"0001104659-26-065908","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Editas disclosed preclinical data for EDIT-401 demonstrating reductions in LDL-C, Lp(a), and ApoB in non-human primates at a major scientific congress. While this is a research update rather than a traditional earnings release, M\u0026A activity, or executive change, the disclosure of positive preclinical efficacy data for a pipeline asset would be material to investors evaluating the company's development progress and therapeutic potential, particularly for a gene-editing biotech company where pipeline advancement is a key value driver.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:06:43.642442+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1405,"accession_number":"0001104659-26-065908","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Editas announced positive preclinical data for EDIT-401 showing robust 90% reductions in LDL-C, Lp(a), and ApoB in non-human primates, along with plans to initiate a first-in-human clinical trial in 2026 and FDA pre-IND feedback. While this is significant clinical development progress for a lead candidate, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, impairment, litigation, or other defined event types). The disclosure is material to investors assessing the company's pipeline advancement and regulatory pathway, but the core event—announcement of preclinical data and clinical trial plans—is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:06:43.642442+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1404,"accession_number":"0001104659-26-065908","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Editas disclosed preclinical data for EDIT-401 demonstrating reductions in LDL-C, Lp(a), and ApoB in non-human primates at a major scientific congress. While this is a research update rather than a traditional earnings release, M\u0026A activity, or executive change, the disclosure of positive preclinical efficacy data for a pipeline asset would be material to investors evaluating the company's development progress and therapeutic potential, particularly for a gene-editing biotech company where pipeline advancement is a key value driver.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:06:43.642442+00:00","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-05-26"},{"id":1405,"accession_number":"0001104659-26-065908","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Editas announced positive preclinical data for EDIT-401 showing robust 90% reductions in LDL-C, Lp(a), and ApoB in non-human primates, along with plans to initiate a first-in-human clinical trial in 2026 and FDA pre-IND feedback. While this is significant clinical development progress for a lead candidate, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, impairment, litigation, or other defined event types). The disclosure is material to investors assessing the company's pipeline advancement and regulatory pathway, but the core event—announcement of preclinical data and clinical trial plans—is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:06:43.642442+00:00","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-05-26"}]}